Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia

Launched by ZHIYONG PENG · Feb 8, 2020

Keywords

ClinConnect Summary

At the end of 2019, patients with unexplained pneumonia appeared in Wuhan, China. At 21:00 on January 7, 2020, a new coronavirus was detected in the laboratory, and the detection of pathogenic nucleic acids was completed at 20:00 on January 10. Subsequently, the World Health Organization officially named the new coronavirus that caused the pneumonia epidemic in Wuhan as 2019 new coronavirus (2019-nCoV), and the pneumonia was named severe acute respiratory infection (SARI). Up to February 4, 2020, over 20000 cases have been diagnosed in China, 406 of which have died, and 154 cases have been ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥ 18 years old;
• • 2. Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and Clinical management of 2019-nCoV infected pneumonia);
• • 3. Being treated in the ICU.
• Exclusion Criteria:
• • 1. Allergic to vitamin C;
• • 2. Dyspnea due to cardiogenic pulmonary edema;
• • 3. Pregnant or breastfeeding;
• • 4. Expected life is less than 24 hours;
• • 5. There is a state of tracheotomy or home oxygen therapy in the past;
• • 6. Previously complicated with end-stage lung disease, end-stage malignancy, glucose-6-phosphate dehydrogenase deficiency, diabetic ketoacidosis, and active kidney stone disease;
• • 7. The patient participates in another clinical trial at the same time.